GNRH TRIPTORELIN 100MCG

GNRH TRIPTORELIN 100MCG

TRIPTORELIN Peptide Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.*Due to the small aliquot of 100mcg, the visible material will be minimal. Triptorelin is a GnRH agonist (referred to as GnRHa, gonadotropin-releasing hormone agonist, a decapeptide). Most of the initial studies were for endometriosis patients. For example, a study in 1996 intended to evaluate the efficacy and adverse effects of monthly triptorelin injection for the treatment of endometriosis: A multicenter clinical trial including 45 women with endometriosis, treated with triptorelin 3.75 mg i.m. every 4 weeks in six consecutive doses. The main outcome measures were symptom relief, reduction according to revised American Fertility Society (rAFS) scores, reduction in size of ovarian endometrioma, effects on hormone and lipid profiles, changes in bone mineral density (BMD), adverse effects, and return of menstruation. Data were analyzed using repeated measures analysis of variance and paired t-tests. RESULTS: Pain-related symptoms decreased in all cases after 8 weeks of treatment. Laparoscopic assessment revealed a reduction in rAFS scores in 21 out of 25 cases (mean pretreatment scores 43.44 5.75 vs. post-treatment scores 22.30 3.40, P < 0.001). The size of ovarian endometrioma decreased in eight of nine women but none disappeared. Serum luteinizing hormone, follicle-stimulating hormone and estradiol levels were effectively suppressed during treatment. A slight increase in cholesterol and triglyceride levels was observed but all values were within normal limits. After 24 weeks of treatment there was a slight decrease in BMD of total body, lumbar vertebrae and femoral neck but not radius. The main adverse effects included hot flushes, night sweating, vaginal dryness, headache, dizziness and nausea Menstruation returned 83.76 2.91 days after the last injection of triptorelin. CONCLUSION: Long-acting triptorelin is efficacious in the treatment of endometriosis and has tolerable side effects. [1] A study performed in 2010 yielded impressive results in a 34 year old male : The patient was 175 cm tall and 80 kg, and he appeared very muscular and toned. His blood pressure and pulse rate were normal. Examination of his heart, lungs, and abdomen were likewise unremarkable. The physical examination showed normal secondary sexual characteristics, but the genital examination revealed bilateral testicular atrophy (volume 2.9 mL and weak consistence). Despite his testicular atrophy, the semen analysis revealed a normal count (79 × x106spermatozoa/mlmL) and mild morphology derangements (between 46% and 58%). The blood count and chemistry were normal, but his level of creatine kinase was 454 IU/L (normal range: 20--170 IU/L), alanine aminotransferase 61 IU/L (normal range: 5--50 IU/L), and aspartate aminotransferase 23 IU/L (normal range: 5--50 IU/L). the patient continued to report loss of libido and great tiredness. A second physical examination was performed. His levels of alanine transferase and creatine kinase were all within the normal range, but the endocrinologic investigations were still abnormal with the exception of sex hormone-binding globulin level. *The patients testosterone measured 0.3 ng/mL - normal range is between 2.0 ng/mL and 12 ng/ML. Because the situation had persisted for months, we administered a single dose (100 μg) of triptorelin, which showed a normal response. Ten days after the triptorelin, the patient reported a great amelioration of energy, and his serum testosterone was 7.0 ng/mL. One month later, his serum testosterone was within the normal range, and he reported a return to normal libido and energy. MAIN OUTCOME MEASURE(S): Clinical symptoms, androgen normalization, levels of serum testosterone, follicle-stimulating hormone, and luteinizing hormone. RESULT(S): Within 1 month, the patient's serum testosterone was in the normal range, and he reported a return to normal energy and libido. [2] In a recent study, done in 2011, Gonadotrophin-releasing hormone agonists (GnRHa) were used in assisted reproduction technology (ART) cycles, comparing long and short protocols: Of 29 included studies, 17 compared long with short protocols; two compared long with ultrashort protocols; four compared a follicular versus luteal start of GnRHa; three compared continuation versus stopping the GnRHa at the start of stimulation; three compared continuation of the same dose versus reduced dose of GnRHa and one compared a short versus short stop protocol.There was no evidence of a difference in the live birth rate but this outcome was only reported by three studies.There was evidence of a significant increase in clinical pregnancy rate (OR 1.50, 95% CI 1.16 to 1.93) in a long protocol when compared to a short protocol. That is there is a 50% increase in chance of achieving pregnancy if a long protocol is used as compared to a short protocol, although this difference could range from 16% to 93% increased chance of pregnancy.[3] The latter article is intended for educational / informational purposes only.

BUY GNRH TRIPTORELIN 100MCG

GNRH TRIPTORELIN WARNING: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law.